pISSN 1226-6051
eISSN 2508-786X

Table. 6.

Table. 6.

Analysis of risk factors of proteinuria


Proteinuria (n=29) Non-proteinuria (n=120) Hazard ratio (95% CI) p-value
Gender, n (%) 0.51
Male 18 (62.1) 73 (60.8) 1.0 (Reference)
Female 11 (37.9) 47 (39.2) 1.15 (0.75-1.77)
Primary site, n (%) 0.59
Colon cancer 16 (55.2) 62 (51.7) 1.0 (Reference)
Rectal cancer 13 (44.8) 58 (48.3) 1.14 (0.70, 1.88)
Recurrence 0.92
No 12 (41.4) 52 (43.3) 1.0 (Reference)
Yes 17 (58.6) 68 (56.7) 1.02 (0.64, 1.64)
Organs metastasized
Lung 0.06
No 15 (51.7) 60 (50.0) 1.0 (Reference)
Yes 14 (48.3) 60 (50.0) 1.56 (0.99, 2.46)
Liver 0.02
No 13 (44.8) 64 (53.3) 1.0 (Reference)
Yes 16 (55.2) 56 (46.7) 1.85 (1.12, 3.05)
Brain 0.69
No 29 (100.0) 119 (99.2) 1.0 (Reference)
Yes 0 (0.0) 1 (0.8) 1.53 (0.19, 12.13)
Bone 0.04
No 29 (100.0) 109 (90.8) 1.0 (Reference)
Yes 0 (0.0) 11 (9.2) 2.27 (1.04, 4.97)
Other organs 0.04
No 22 (75.9) 95 (79.2) 1.0 (Reference)
Yes 7 (24.1) 25 (20.8) 1.85 (1.04, 3.26)
Surgery 0.01
No 4 (13.8) 11 (9.2) 1.0 (Reference)
Yes 25 (86.2) 109 (90.8) 0.42 (0.22, 0.80)
Radiation therapy 0.20
No 18 (62.1) 78 (65.0) 1.0 (Reference)
Yes 11 (20.8) 42 (35.0) 1.41 (0.84, 2.35)
Chemotherapy with bevacizumab
Capecitabine + bevacizumab 2 (6.9) 0 (0.0) 1.0 (Reference)
FL + bevacizumab 1 (3.5) 7 (5.8) 0.87 (0.16, 4.74) 0.87
FOLFIRI + bevacizumab 17 (58.6) 75 (62.5) 0.17 (0.04, 0.83) 0.03
FOLFOX + bevacizumab 9 (31.0) 38 (31.7) 0.17 (0.04, 0.81) 0.03
Previous adjuvant chemotherapy 0.42
No 7 (24.1) 33 (27.5) 1.0 (Reference)
Yes 22 (75.9) 87 (72.5) 1.29 (0.70, 2.4)
Previous adjuvant chemotherapy including Bevacizumab 0.36
No 21 (72.4) 102 (85.0) 1.0 (Reference)
Yes 8 (27.6) 18 (15.0) 1.28 (0.76, 2.17)

P value were calculated using cox-proportional regression analysis.

FL: 5-Fluorouracil, leucovorin, FOLFIRI: 5-Fluorouracil, leucovorin, irinotecan, FOLFOX: 5-Fluorouracil, leucovorin, oxaliplatin

Korean J Clin Pharm 2020;30:234-42 https://doi.org/10.24304/kjcp.2020.30.4.234
© 2020 Korean J Clin Pharm